Literature DB >> 1309967

Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages.

J Dhillon1, D A Mitchison.   

Abstract

The activities of the rifamycins, rifabutin, FCE 22807, rifapentine, and rifampin, were studied within unstimulated peritoneal macrophages infected with Mycobacterium microti and in cultures of M. microti and M. tuberculosis in 7H-9 medium without Tween 80. In macrophage cultures, serial rifamycin concentrations were added after a 2.5 h phagocytosis period, and viable counts were done after incubation for 5 to 6 days. To ensure comparability with the daily drug replacements in the macrophage experiments, the period of exposure to serial rifamycin concentrations in 7H-9 medium was kept to only 3 days. The MICs of M. microti and M. tuberculosis were similar. The MICs of rifabutin and FCE 22807 were 2.5 times lower and that of rifapentine 1.7 times lower than the MIC of rifampin. None of the rifamycins were concentrated in macrophages, the MICs being higher in the macrophages than in vitro by a factor of 2-fold for rifabutin, 6.7-fold for rifampin, 20-fold for FCE 22807, and 26-fold for rifapentine.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1309967     DOI: 10.1164/ajrccm/145.1.212

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  16 in total

1.  Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media.

Authors:  G E Pfyffer; D A Bonato; A Ebrahimzadeh; W Gross; J Hotaling; J Kornblum; A Laszlo; G Roberts; M Salfinger; F Wittwer; S Siddiqi
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

2.  Single-dose intrapulmonary pharmacokinetics of rifapentine in normal subjects.

Authors:  J E Conte; J A Golden; M McQuitty; J Kipps; E T Lin; E Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

Review 3.  Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Mycobacterium microti--pulmonary tuberculosis in an immunocompetent patient.

Authors:  Wolfgang Frank; Emil C Reisinger; Wiltrud Brandt-Hamerla; Ilona Schwede; Werner Handrick
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

5.  Development of rifapentine susceptibility tests for Mycobacterium tuberculosis.

Authors:  L Heifets; T Sanchez; J Vanderkolk; V Pham
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

6.  Reporter gene technology to assess activity of antimycobacterial agents in macrophages.

Authors:  T M Arain; A E Resconi; D C Singh; C K Stover
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

7.  Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis.

Authors:  B P Kelly; S K Furney; M T Jessen; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

8.  Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages.

Authors:  N Mor; B Simon; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

9.  Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin.

Authors:  John E Conte; Jeffrey A Golden; Juliana E Kipps; Emil T Lin; Elisabeth Zurlinden
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

10.  Evaluation of once-weekly therapy for tuberculosis using isoniazid plus rifamycins in the mouse aerosol infection model.

Authors:  J V Brooks; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.